https://www.selleckchem.com/pr....oducts/PHA-793887.ht
001) were more likely to achieve PR than their counterparts. NET prescription failed to increase BCS conversion rates for patients with RS18 (OR 0.23, 95% CI 0.04-1.47, P=0.12 and RS30 (OR 1.27, 95% CI 0.64-2.49, P=0.49 respectively. Only 22 patients achieved pCR (2.8%) and RS group failed to predict pCR following NET (P=0.85. Estimations from this analysis indicate that those with low-intermediate RS on core biopsy are four times more likely to respond to NET than those with high-risk RS. Performing RS testing on diagn
Me gusta
Comentario
Compartir
